Seaport Therapeutics, Inc. (SPTX) · Nov 2, 2026 · Earnings
Beat — EPS loss of $0.49 vs ~$0.58 consensus
Seaport Therapeutics earnings narrowly beat the loss estimate while GlyphAllo and GlyphAgo advance toward major 2027 clinical milestones.
Seaport is a cash-rich, clinical-stage neuropsychiatry company using its Glyph platform to move oral versions of validated drug mechanisms into mid-stage testing. Before this filing, the main story was already defined: GlyphAllo was advancing through the Phase 2b BUOY-1 trial in major depressive disorder, while GlyphAgo was moving toward Phase 2 testing in generalized anxiety disorder; the company had also already disclosed a 2029 cash runway and expected the driving-simulation data in the second half of 2026.
The quarter modestly beats the financial bar, but does not change the business story. Seaport reported a $0.49 per-share loss versus a published estimate of roughly $0.58, making this a narrow earnings beat rather than a major operating surprise. The loss still widened year over year as clinical spending increased, with R&D rising to $23.9 million and total net loss reaching $26.4 million.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss (Financial Results) | $26.4M | $22.5M | |
| Net loss per share (Financial Results) | $(0.49) | $(9.43) | $(0.58) |
| R&D expense (Financial Results) | $23.9M | $20.5M | |
| Cash, equivalents and investments (Balance Sheet) | $403.8M | $233.7M at Dec. 31, 2025 |
Clinical execution remains on schedule, but most of the good news was already public. The filing confirms that BUOY-1 enrollment remains on track for a first-half 2027 readout and that the first patient has been dosed in the GlyphAgo Phase 2a trial. It also repeats the positive GlyphAllo driving-simulation result, which was separately announced in September, so these are confirmations of execution rather than fresh clinical data. 〔0〕
Funding is sufficient for the next major tests, not proof of clinical success. Seaport ended September with $403.8 million in cash, equivalents and investments and reiterated that this supports operations into 2029, covering three mid-to-late-stage readouts. 〔1〕 That removes near-term financing pressure from the current story, but the value of the pipeline still depends on the upcoming efficacy data rather than this quarter's financial results.
Bottom line: This is a narrow earnings beat and a clean progress report, but not a story reset. Seaport is executing on its planned clinical timeline with enough cash to reach the important readouts; the genuinely consequential test remains BUOY-1 data in the first half of 2027.
BUOY-1 topline data, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!